The law firm of Kirby McInerney LLP announced today an investigation on behalf of investors of Trinity Biotech plc ("Trinity" or the "Company") (NASDAQ:TRIB) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

Trinity acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.

The investigation concerns Trinity's October 4, 2016 announcement that the Company was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the recommendation of the U.S. Food and Drug Administration. On news of the withdrawal, Trinity's share price fell over 50% to close at just $6.46 per share on October 4, 2016, thereby injuring investors.

If you purchased or otherwise acquired shares of Trinity and would like more information pertaining to the investigation, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600 or by email at to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars, and the firm's achievements and quality of service have been chronicled in numerous published decisions. Additional information about the firm can be found at Kirby McInerney LLP's website:

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010